Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Genomics and Precision Health Database


Genomics & Health Impact Scan Database|Search|PHGKB
Last data update: Dec 28, 2020. (Total: 37862 Documents since 2012)
   dataset
Filtered By:
Records 1-13 (of 13 Record(s))
Query Trace: Melanoma[original query]>>Guidelines[Product Type]
Publication
Prognostic Gene Expression Profiling in Cutaneous Melanoma Identifying the Knowledge Gaps and Assessing the Clinical Benefit
D Grossman et al, JAMA Dermatology, July 29, 2020
[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].
Rose C et al. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2017 Sep 68(9) 749-761
[Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].
Rose C et al. Der Pathologe 2017 Feb 38(1) 49-61
Guidelines of care for the management of primary cutaneous melanoma.
Swetter Susan M et al. Journal of the American Academy of Dermatology 2019 80(1) 208-250
Local Coverage Determination (LCD): Genetic Testing for Lynch Syndrome (L34912)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): BRCA1 and BRCA2 Genetic Testing (L36715)
The U.S. Centers for Medicare & Medicaid Services
Local Coverage Determination (LCD): BRCA1 and BRCA2 Genetic Testing (L36499)
The U.S. Centers for Medicare & Medicaid Services
PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.
Schultz Kris Ann P et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 Jun 23(12) e76-e82
Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement.
, et al. JAMA 2016 7 0. (4) 429-35
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
NICE guidance on vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma.
BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.
TOP